HOUSTON, March 19, 2019 /PRNewswire/ -- Soliton,
Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device
company with a novel and proprietary platform technology licensed
from The University of Texas on behalf
of the MD Anderson Cancer Center ("MD Anderson"), completed the
human trials of its proprietary Rapid Acoustic Pulse (RAP) Device
to support the Company's FDA 510(k) submission. The Company
conducted three rounds of human trials to study the use of the RAP
device to accelerate tattoo fading.
------------------------
Join our more than 208K fans here
to follow the Company: https://soly-investors.com
------------------------
"The human trials provided evidence of the potential for the RAP
technology to accelerate tattoo fading," said Dr. Chris Capelli, Soliton's President and CEO. "The
combination treatment of the RAP device and a laser outperformed a
laser alone, showing an average of 80% fading after only two visits
vs 44% fading for the laser alone. After 3 Soliton Multi-Pass
treatments, 100% of the treated tattoos had a 'Complete' (76-100%
faded) response; in comparison, only 17% of the tattoos treated
with the Laser Only had a 'Complete' response."
About Soliton, Inc.
Soliton, Inc. is a medical device company with a novel and
proprietary platform technology licensed from MD Anderson. The
Company's first planned commercial product is designed to use rapid
pulses of designed acoustic shockwaves in conjunction with existing
lasers to accelerate the removal of unwanted tattoos (RAP device).
In addition, higher energy versions of acoustic pulse devices are
in early stages of development for potential stand-alone treatment
of cellulite and other indications. Both products are
investigational and are not available for sale in the United States.
For more information about the Company, please
visit: http://www.soliton.com
Forward-Looking Statements
Some of the statements in this release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. Forward-looking statements in this press
release include, without limitation, the ability of Soliton RAP to
receive FDA clearance. These statements relate to future
events, future expectations, plans and prospects. Although Soliton
believes that the expectations reflected in such forward-looking
statements are reasonable as of the date made, expectations may
prove to have been materially different from the results expressed
or implied by such forward-looking statements. Soliton has
attempted to identify forward-looking statements by terminology
including ''believes,'' ''estimates,'' ''anticipates,''
''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,''
''may,'' ''could,'' ''might,'' ''will,'' ''should,''
''approximately'' or other words that convey uncertainty of future
events or outcomes to identify these forward-looking statements.
These statements are only predictions and involve known and unknown
risks, uncertainties, and other factors, including those discussed
under in our SEC filings, including under the heading "Risk
Factors" in the Form 1-A we filed with the SEC on February 13, 2019. Any forward-looking
statements contained in this release speak only as of its date.
Soliton undertakes no obligation to update any forward-looking
statements contained in this release to reflect events or
circumstances occurring after its date or to reflect the occurrence
of unanticipated events.
CONTACT:
|
Joe Dorame, Joe
Diaz & Robert Blum
|
|
Lytham Partners,
LLC
|
|
602-889-9700
|
|
soly@lythampartners.com
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/soliton-completes-clinical-trials-for-initial-fda-filing-for-tattoo-indication-300814386.html
SOURCE Soliton, Inc.